Recently, the University of Oxford began an international study to examine the potential therapeutic benefits of cannabidiol (CBD) in treating psychosis or psychotic symptoms.
On February 13, 2023, the US Drug Enforcement Administration (DEA) declared in a letter that the cannabinoids delta-8 and -9 THCO are both considered controlled substances due to their chemical structures.
The House and Senate introduced a revised bill to mandate Veterans Affairs (VA) to conduct research on the effects of medical cannabis on veterans with post-traumatic stress disorder (PTSD) and chronic pain.
Cannabidiol (CBD) was recently studied in Mexico as a treatment for traumatic brain injury and Parkinson’s Disease.
Next month the University of Connecticut (UConn) will hold a two-day cannabis symposium covering a wide variety of topics.
Starting July 1, 2023, Australia will allow the use of psilocybin and 3,4-Methylenedioxymethamphetamine (MDMA) for therapeutic use in a medical setting to treat mental health conditions.
In response to a call for comment on the proposed New York Office of Cannabis Management symbol, the Doctors for Cannabis Regulation submitted a letter outlining the design flaws of the proposed symbol and recommended adopting the International Intoxicating Cannabinoid Product Symbol instead.
A statement released on Thursday, January 26, 2023 from Dr. Janet Woodcock, the principal deputy commissioner of the Food and Drug Administration (FDA), announced that the FDA will work with Congress in formulating regulatory oversight to balance risk and access for products in the cannabidiol (CBD) market.
As access to edible cannabis increases for adults across the United States, children are also becoming more exposed as well.
Results from recently published survey studies on the effect of psilocybin and bipolar disorder offered support for the design of future clinical trials.
This 1 CME credit article evaluates evidence-based behavioral treatments, medications, and management strategies for cannabis use disorder.
A study published in January 2023 examined the effects of high and low doses of cannabigerol (CBG) on mice liver.
In late 2022, Leaf411, a cannabis-trained nurse guidance service, announced that they resumed their affordability program for patients struggling to pay for their medicine. In a recent update, Leaf411 outlined their continued response to requests for assistance they are receiving from across the country.
The study, which began before states started legalizing cannabis, published its results on the impact of a legal cannabis environment on cannabis use and alcohol use disorder.
Josee Guindon, DVM, PhD of Texas Tech University Health Sciences Center, was named as the recipient for this award, which recognizes dedication, perseverance, and skill in studying and researching the endocannabinoid system.
A farmer in Ireland who was arrested for growing and selling cannabis from his farm received a suspended sentence. Currently, cannabis is illegal in Ireland, except within a limited medical program.
A recent study from the University of Connecticut showed that the new “retipping” method of propagation resulted in quality cannabis flowers while using less space.
In results from a recent study, respondents reported that cannabis use led them to decrease their use of pharmacological treatments, including opioids.
Starting January 1, 2023, every insurance provider in Colombia must cover the costs of medical cannabis prescriptions for patients.
Village Farms International, Inc., announced that starting later this month it will increase its global presence by beginning to ship cannabis products to the Israeli medical market.
In December, the US Department of Agriculture (USDA) announced an extension of the deadline for all hemp to be tested for tetrahydrocannabinol (THC) in Drug Enforcement Administration (DEA)-certified facilities only, citing a lack of approved laboratories.
Brittany Griner had been arrested in Moscow, Russia and sentenced to prison for cannabis possession, which is illegal in Russia.
On December 2nd, 2022, President Joe Biden signed the Medical Marijuana and Cannabidiol Research Expansion Act, the first piece of standalone cannabis legislation in US history to become law. It will reportedly streamline a new process for cannabis research applications and for manufacturing products for drug development and allow for a larger amount of legal cannabis for research purposes.
In partnership with the Cannabis Center of Excellence, MCR Labs Massachusetts held their second “Cannabis Science Fair” on the afternoon of December 3rd, 2022, as the final event of their Science Over Stigma campaign.
In their 2022 Census of Agriculture, the US Department of Agriculture will, for the first time, collect and publish data on farmers and producers who grow hemp for fabric, food products, and cannabidiol (CBD).
The Cannabis & Me research study will reportedly study the effects of cannabis on the human brain, particularly in terms of a user’s prior psychological conditions.
International company PQE Group announced in late October their first ever start-up to provide support for medical cannabis.
For the first time, the Association of Official Analytical Collaboration (AOAC) INTERNATIONAL Research Institute granted its Reviewed and Recognized certification to a cannabis potency testing laboratory.
Earlier this month, Committee D37 on Cannabis, a committee within ASTM International, released descriptions of their four new standards for cannabis testing and who they will benefit within the industry.
In a recent announcement, Major League Baseball announced a sponsorship deal with cannabidiol (CBD) company Charlotte’s Web.
